Author

Paul David Abel

Observed names: Abel, Paul, Abel, Paul D, Abel, Paul David, DP Abel, PAUL D. ABEL, Paul Abel, Paul Abel Y, Paul Abel Z, Paul Abel‡, Paul D Abel, Paul D. Abel

Institution: Imperial College London

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University College Hospital, Imperial College Healthcare NHS Trust, China Medical University, Justus-Liebig-Universität Gießen, The Royal Free Hospital, Hammersmith Hospital, Charing Cross Hospital, Royal Liverpool University Hospital, London School of Hygiene & Tropical Medicine, Queen Charlotte's and Chelsea Hospital, China Medical University Hospital, Chelsea and Westminster Hospital, University College London, Imperial College London, University of Birmingham

OpenAlex ID: A5110114367

bcl-2: Role in epithelial differentiation and oncogenesis

1996 · Qi-Long Lu, Paul Abel, et al. · Human Pathology · 265

Masculinity, infertility, stigma and media reports

2004 · Kenneth Gannon, Lesley Glover, et al. · Social Science & Medicine · 154

Impact of surgery for stress incontinence on morbidity: cohort study

1997 · Nick Black, Joanne Griffiths, et al. · BMJ · 151

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

2013 · Ruth E Langley, Fay H Cafferty, et al. · The Lancet Oncology · 93

Molecular and cellular biology of prostate cancer

1997 · El-Nasir Lalani, Marc Elie Laniado, et al. · Cancer and Metastasis Reviews · 92

Phosphorylation of Both EGFR and ErbB2 Is a Reliable Predictor of Prostate Cancer Cell Proliferation in Response to EGF

2004 · Soha Salama El Sheikh, Jan Domin, et al. · Neoplasia · 91

PDF

Re-constructing masculinity following radical prostatectomy for prostate cancer

2010 · Kenneth Gannon, Monica Guerro-Blanco, et al. · The Aging Male · 85

PDF

Tumor focality in prostate cancer: implications for focal therapy

2010 · Markos Karavitakis, Hashim U. Ahmed, et al. · Nature Reviews Clinical Oncology · 81

Development of the fertility adjustment scale

1999 · Lesley Glover, Myra Hunter, et al. · Fertility and Sterility · 75

MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: Correlation with prognosis

2002 · Sigurd Kraus, Paul D. Abel, et al. · Human Pathology · 57

Androgen-Dependent Regulation of Human MUC1 Mucin Expression

2002 · Stephen Mitchell, Paul Abel, et al. · Neoplasia · 53

PDF

Quality‐of‐life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones ( PATCH ) trial evaluating luteinising hormone‐releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

2016 · Duncan C. Gilbert, Trinh Duong, et al. · British Journal of Urology · 52

PDF

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first‐line hormonal therapy in patients with locally advanced or metastatic prostate cancer

2008 · Ruth E. Langley, Ian F. Godsland, et al. · British Journal of Urology · 50

Transdermal Estradiol Therapy for Prostate Cancer Reduces Thrombophilic Activation and Protects Against Thromboembolism

2005 · JEREMY L. OCKRIM, EL-NASIR LALANI, et al. · The Journal of Urology · 49

Human MUC1 mucin: a potent glandular morphogen

2001 · Mark J. Hudson, Gordon W. Stamp, et al. · The Journal of Pathology · 46

Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study

2008 · Soha Salama El Sheikh, Hanna M. Romanska, et al. · Neoplasia · 44

PDF

Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation

2003 · Soha Salama El Sheikh, Jan Domin, et al. · BMC Clinical Pathology · 42

PDF

Differentially Expressed Genes in Hormone Refractory Prostate Cancer

1999 · Andrew P. Stubbs, Paul D. Abel, et al. · American Journal Of Pathology · 37

PDF

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

2015 · Ruth E. Langley, Howard G. Kynaston, et al. · European Urology · 35

PDF

Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy

2006 · Jeremy Ockrim, El-Nasir Lalani, et al. · Nature Clinical Practice Oncology · 34

Female Urinary Genuine Stress Incontinence: Anatomic Considerations at MR Imaging of the Paravaginal Fascia and Urethra—Initial Observations

2002 · Nandita M. deSouza, O. Joseph Daniels, et al. · Radiology · 34

Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells

2001 · Khurram S. Chaudhary, Paul D. Abel, et al. · The Journal of Pathology · 32

Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors

1994 · Pieter C. Dagnelie, Jimmy D. Bell, et al. · Lipids · 32

TFF2 (trefoil family factor2) inhibits apoptosis in breast and colorectal cancer cell lines

2004 · Lai-San Siu, Hanna Romanska, et al. · Peptides · 31

Androgen-Independent Prostate Cancer: Potential Role of Androgen and ErbB Receptor Signal Transduction Crosstalk

2003 · Soha Salama El Sheikh, Jan Domin, et al. · Neoplasia · 31

PDF

Works count: 115

Citation count: 2,160

H-index: 27

I10-index: 43